Biologic therapies for chronic obstructive pulmonary disease. (1st February 2023)

• Record Type: Journal Article
• Authors: Matera, Maria Gabriella; Calzetta, Luigino; Cazzola, Mario; Ora, Josuel; Rogliani, Paola
• Is Part Of: Expert opinion on biological therapy. Volume 23:Number 2(2023)
• Page Start: 163
• Page End: 173
• Publication Date: 2023-02-01
• Subjects: COPD -- chronic inflammation -- cytokines -- chemokines -- monoclonal antibodies; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2022.2160238
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: Chronic obstructive pulmonary disease (COPD) is a disorder characterized by a complicated chronic inflammatory response that is resistant to corticosteroid therapy. As a result, there is a critical need for effective anti-inflammatory medications to treat people with COPD. Using monoclonal antibodies (mAbs) to inhibit cytokines and chemokines or their receptors could be a potential approach to treating the inflammatory component of COPD. Areas covered: The therapeutic potential that some of these mAbs might have in COPD is reviewed. Expert opinion: No mAb directed against cytokines or chemokines has shown any therapeutic impact in COPD patients, apart from mAbs targeting the IL-5 pathway that appear to have statistically significant, albeit weak, effect in patients with eosinophilic COPD. This may reflect the complexity of COPD, in which no single cytokine or chemokine has a dominant role. Because the umbrella term COPD encompasses several endotypes with diverse underlying processes, mAbs targeting specific cytokines or chemokines should most likely be evaluated in limited and focused populations.